following an abbreviated submission:
foslevodopa-foscarbidopa (Produodopa®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.
SMC restriction: for use in patients not eligible for deep brain stimulation (DBS).
Foslevodopa-foscarbidopa offers an additional treatment choice in the therapeutic class of dopa and dopa derivatives for this indication.
Another medicine within this therapeutic class has been accepted via the orphan medicine process for this indication.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice253KB (PDF)
Medicine details
- Medicine name:
- foslevodopa-foscarbidopa (Produodopa)
- SMC ID:
- SMC2574
- Indication:
Treatment of advanced levodopa-responsive Parkinson’s disease (PD) with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 11 March 2024